– USA, CA – Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, announced the appointment of Dr. Emil Kakkis (M.D., Ph.D.) to its board of directors.
“Few individuals in our industry possess a combination of personal commitment, scientific integrity and exceptional business acumen that Emil has fostered throughout his career, and we are honored to welcome him to the Actio board. His insights, expertise and passion will be invaluable to the company’s long-term commitment to developing first in class life-changing medicines.” said Board Chair, Dr. George Golumbeski.
About Dr. Emil Kakkis
Dr. Emil Kakkis, a visionary in rare disease drug development, founded Ultragenyx in 2010 to create a company that is uniquely built around a deep and meaningful engagement with patients and their caregivers to fully understand their needs.
“Having seen the impact that the development of innovative medicines can have on patients living with rare diseases and their families, I am motivated by Actio’s focus on developing small molecule treatments that effectively target the precise underlying biology and cause of rare diseases,” said Dr. Emil Kakkis. “I am pleased to join the company’s board of directors as we work toward a collective goal focused not only on addressing rare conditions with no treatments today, but potentially addressing more common diseases that lack effective treatment options.”
Dr. Kakkis began his career at the Harbor-UCLA Medical Center, where he led work to develop an enzyme replacement therapy for the rare disorder MPS I. He joined BioMarin in 1998, where he guided the development and approval of three treatments for rare diseases and contributed to the development of approved or development-stage products for four other rare indications. He has worked to advance the cause of rare disease treatment through advocacy on policy issues by founding and supporting the EveryLife Foundation for Rare Diseases, a nonprofit foundation dedicated to the acceleration of biotech innovation for rare diseases through practical and scientifically sound improvements to the development strategies, regulatory policy, and law. Dr. Kakkis received combined M.D. and Ph.D. degrees from the UCLA Medical Scientist Program and received the Bogen Prize for his research upon graduation. He completed a pediatrics residency and a Medical Genetics Training Fellowship at Harbor-UCLA Medical Center, where he was an assistant professor of pediatrics and initiated the enzyme therapy program for MPS I. Dr. Kakkis has received numerous awards including the Life Science Leadership Pantheon award from California Life Sciences, a Lifetime Achievement Award from the National MPS Society, the Roscoe O Brady Award for innovation from the WORLD Symposium and the Henri Termeer Visionary Leader Award from BIO, the biotechnology innovation organization.
About Actio Biosciences
Actio Biosciences is leveraging advances in precision medicine to develop new therapeutics that target shared genetics in rare and common diseases—bringing meaningful medicines from one to many. Applying its expertise in genetics, drug discovery, and data sciences, Actio seeks to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics. Founded in October 2021, the San Diego-based company is led by leaders in genetics and drug development and backed by top healthcare investors.
For more information: https://actiobiosciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.